Systemic administration of AXA-042, a novel TLR2/6 agonist, reshapes the tumor microenvironment, as revealed by single cell sequencing analysis.

AXA-042 - Axelia Oncology

https://jitc.bmj.com/content/10/Suppl_2/A1205

Bedrich Eckhardt 1; Kellie Mouchemore 1; Yang Liao 1; Wei Shi 1; Francesca Mercuri 2; Phil Kearney 3; Robin Anderson 1; Anna Galkin 3

Oct 6, 2022